Monday, May 05, 2025 11:48:00 AM
Business Summary
Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. It also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances. In addition, the company develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use in as health supplements and medications. Impact BioMedical Inc. was incorporated in 2018 and is based in Houston, Texas.
Recent IBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2026 09:52:44 PM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 12/30/2025 09:30:27 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 12/11/2025 10:11:47 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2025 09:30:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2025 09:07:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2025 08:05:40 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 09/22/2025 08:40:46 PM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 09/09/2025 09:03:32 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 08/26/2025 01:14:40 PM
- Impact Biomedical Inc (IBO) Announces 3F™ US Patent Issue • GlobeNewswire Inc. • 08/18/2025 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 04:28:15 PM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 08/05/2025 08:33:18 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 07/16/2025 08:30:05 PM
- Dr Ashleys Limited and Impact BioMedical Inc. Announce Strategic Merger • GlobeNewswire Inc. • 06/23/2025 11:52:44 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/23/2025 11:45:39 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2025 08:15:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/03/2025 08:29:33 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/28/2025 08:15:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/28/2025 01:00:13 PM
- Impact Biomedical Inc. Announcement Stock Activity/Pricing • GlobeNewswire Inc. • 03/21/2025 06:38:33 PM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM
C2 Blockchain Reports 803 Million DOG (Bitcoin) Holdings Following Strategic Accumulation of Bitcoin-Native Digital Assets • CBLO • Mar 10, 2026 8:00 AM
RENI Completes Due Diligence on Target Acquisition; Confirms Strong Asset Base and Operational Performance • RENI • Mar 5, 2026 10:15 AM
BlackStar Engages in Talks with U.S. Senate Banking Committee Team Covering the Digital Asset Market Clarity Act • BEGI • Mar 4, 2026 4:47 PM
